EDP-2939 is under clinical development by Evelo Biosciences and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EDP-2939’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EDP-2939 overview

EDP-2939 is under development for the treatment of skin inflammatory disease including plaque psoriasis. The drug candidate are administered through oral route. These are microbiome-based therapeutics (monoclonal microbials).

It was also under development for the treatment of metabolic disorders such as malnutrition, type 2 diabetes, obesity, nonalcoholic fatty liver disease, heart disease.

Evelo Biosciences overview

Evelo Biosciences is a biotechnology company. It develops orally delivered product candidates for the treatment of inflammatory diseases and cancer. The company is investigating pipeline product EDP1815 and EDP1867, targeting SARS-CoV-2 virus, psoriasis, atopic dermatitis, and inflammatory diseases; and EDP1908, an anti-PD-1 therapy for multiple cancers. Its proprietary Sintax, an integrated platform develops oral biologics which harness the cells in the small intestine. Evelo Biosciences is also evaluating novel therapies to treat chronic diseases and cancer. The company’s Evelo is a trademark of Evelo Biosciences. It has its operations in the US, and the UK. Evelo Biosciences is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of EDP-2939’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.